ArticleFuture oncology (London, England)2025

STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.

Sumanta K Pal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.